202 related articles for article (PubMed ID: 21466449)
21. Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus.
Hashimotodani Y; Ohno-Shosaku T; Kano M
J Neurosci; 2007 Jan; 27(5):1211-9. PubMed ID: 17267577
[TBL] [Abstract][Full Text] [Related]
22. Molecular biology of the enzymes that degrade endocannabinoids.
Puffenbarger RA
Curr Drug Targets CNS Neurol Disord; 2005 Dec; 4(6):625-31. PubMed ID: 16375680
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol.
Ghafouri N; Tiger G; Razdan RK; Mahadevan A; Pertwee RG; Martin BR; Fowler CJ
Br J Pharmacol; 2004 Nov; 143(6):774-84. PubMed ID: 15492019
[TBL] [Abstract][Full Text] [Related]
24. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?
Bajaj S; Jain S; Vyas P; Bawa S; Vohora D
Brain Res Bull; 2021 Sep; 174():305-322. PubMed ID: 34217798
[TBL] [Abstract][Full Text] [Related]
25. Metabolism of endocannabinoids.
Biernacki M; Skrzydlewska E
Postepy Hig Med Dosw (Online); 2016 Aug; 70(0):830-43. PubMed ID: 27516570
[TBL] [Abstract][Full Text] [Related]
26. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
27. Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.
Saario SM; Poso A; Juvonen RO; Järvinen T; Salo-Ahen OM
J Med Chem; 2006 Jul; 49(15):4650-6. PubMed ID: 16854070
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
Vandevoorde S; Fowler CJ
Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
[TBL] [Abstract][Full Text] [Related]
29. Cannabinergic ligands.
Palmer SL; Thakur GA; Makriyannis A
Chem Phys Lipids; 2002 Dec; 121(1-2):3-19. PubMed ID: 12505686
[TBL] [Abstract][Full Text] [Related]
30. Fatty acid amide hydrolase but not monoacyl glycerol lipase controls cell death induced by the endocannabinoid 2-arachidonoyl glycerol in hepatic cell populations.
Siegmund SV; Wojtalla A; Schlosser M; Zimmer A; Singer MV
Biochem Biophys Res Commun; 2013 Jul; 437(1):48-54. PubMed ID: 23806692
[TBL] [Abstract][Full Text] [Related]
31. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
Petrosino S; Di Marzo V
Curr Opin Investig Drugs; 2010 Jan; 11(1):51-62. PubMed ID: 20047159
[TBL] [Abstract][Full Text] [Related]
32. Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model.
Desroches J; Guindon J; Lambert C; Beaulieu P
Br J Pharmacol; 2008 Nov; 155(6):913-24. PubMed ID: 18695638
[TBL] [Abstract][Full Text] [Related]
33. The medicinal chemistry of agents targeting monoacylglycerol lipase.
Viso A; Cisneros JA; Ortega-Gutiérrez S
Curr Top Med Chem; 2008; 8(3):231-46. PubMed ID: 18289090
[TBL] [Abstract][Full Text] [Related]
34. The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humans.
Cable JC; Tan GD; Alexander SP; O'Sullivan SE
Lipids Health Dis; 2011 Aug; 10():129. PubMed ID: 21813022
[TBL] [Abstract][Full Text] [Related]
35. No more pain upon Gq-protein-coupled receptor activation: role of endocannabinoids.
Hu SS; Ho YC; Chiou LC
Eur J Neurosci; 2014 Feb; 39(3):467-84. PubMed ID: 24494686
[TBL] [Abstract][Full Text] [Related]
36. The endogenous cannabinoid system and its role in nociceptive behavior.
Cravatt BF; Lichtman AH
J Neurobiol; 2004 Oct; 61(1):149-60. PubMed ID: 15362158
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system-related genes in the rat amygdala.
Serrano A; Rivera P; Pavon FJ; Decara J; Suárez J; Rodriguez de Fonseca F; Parsons LH
Alcohol Clin Exp Res; 2012 Jun; 36(6):984-94. PubMed ID: 22141465
[TBL] [Abstract][Full Text] [Related]
38. Endocannabinoid mechanisms of pain modulation.
Hohmann AG; Suplita RL
AAPS J; 2006 Nov; 8(4):E693-708. PubMed ID: 17233533
[TBL] [Abstract][Full Text] [Related]
39. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
van der Stelt M; van Kuik JA; Bari M; van Zadelhoff G; Leeflang BR; Veldink GA; Finazzi-Agrò A; Vliegenthart JF; Maccarrone M
J Med Chem; 2002 Aug; 45(17):3709-20. PubMed ID: 12166944
[TBL] [Abstract][Full Text] [Related]
40. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
